hydroxychloroquine has been researched along with MODS in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure." | 1.56 | Early experience with remdesivir in SARS-CoV-2 pneumonia. ( Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R, 2020) |
| "Hydroxychloroquine (HCQ) use was found as a protective factor for CVD." | 1.43 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. ( Alpay-Kanıtez, N; Aral, O; Artim-Esen, B; Demir, S; Erer, B; Gül, A; İnanç, M; Kamalı, S; Öcal, L; Omma, A; Pehlivan, Ö; Şahinkaya, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dariya, B | 1 |
| Nagaraju, GP | 1 |
| Durante-Mangoni, E | 1 |
| Andini, R | 1 |
| Bertolino, L | 1 |
| Mele, F | 1 |
| Florio, LL | 1 |
| Murino, P | 1 |
| Corcione, A | 1 |
| Zampino, R | 1 |
| Wu, J | 1 |
| Dirim, AB | 1 |
| Demir, E | 1 |
| Ucar, AR | 1 |
| Garayeva, N | 1 |
| Safak, S | 1 |
| Oto, OA | 1 |
| Yazici, H | 1 |
| Alibeyoglu, AM | 1 |
| Orhun, G | 1 |
| Cagatay, AA | 1 |
| Turkmen, A | 1 |
| Iannaccone, G | 1 |
| Scacciavillani, R | 1 |
| Del Buono, MG | 1 |
| Camilli, M | 1 |
| Ronco, C | 1 |
| Lavie, CJ | 1 |
| Abbate, A | 1 |
| Crea, F | 1 |
| Massetti, M | 1 |
| Aspromonte, N | 1 |
| Croft, A | 1 |
| Bucca, A | 1 |
| Jansen, JH | 1 |
| Motzkus, C | 1 |
| Herbert, A | 1 |
| Wang, A | 1 |
| Hunter, BR | 1 |
| Demir, S | 1 |
| Artim-Esen, B | 1 |
| Şahinkaya, Y | 1 |
| Pehlivan, Ö | 1 |
| Alpay-Kanıtez, N | 1 |
| Omma, A | 1 |
| Erer, B | 1 |
| Kamalı, S | 1 |
| Gül, A | 1 |
| Aral, O | 1 |
| Öcal, L | 1 |
| İnanç, M | 1 |
| Muthukrishnan, P | 1 |
| Roukoz, H | 1 |
| Grafton, G | 1 |
| Jessurun, J | 1 |
| Colvin-Adams, M | 1 |
3 reviews available for hydroxychloroquine and MODS
| Article | Year |
|---|---|
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbid | 2020 |
Tackle the free radicals damage in COVID-19.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Azithromycin; Betacoronavirus; Clinical Trials | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis | 2020 |
5 other studies available for hydroxychloroquine and MODS
| Article | Year |
|---|---|
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Fatal SARS-CoV-2 infection in a renal transplant recipient.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Deterioration; Coronavirus Infections; COV | 2020 |
First-time Diabetic Ketoacidosis in Type 2 Diabetics With Covid-19 Infection: A Novel Case Series.
Topics: Anti-Bacterial Agents; COVID-19; Crystalloid Solutions; Diabetes Mellitus, Type 2; Diabetic Ketoacid | 2020 |
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular Diseases; Cross-Sectional | 2016 |
Hydroxychloroquine-induced cardiomyopathy: a case report.
Topics: Biopsy; Cardiac Resynchronization Therapy; Cardiomyopathies; Cardiovascular Agents; Defibrillators, | 2011 |